ArticleActa obstetricia et gynecologica Scandinavica2025
Risk factors associated with progression from pre-eclampsia to eclampsia: A prospective cohort study and population-wide data analysis.
Article in Acta obstetricia et gynecologica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Diagnostic Concordance and Misclassification of Pre-Eclampsia in a Malaria-Endemic Setting: A Comparative Cross-Sectional Study.BioMed research international · 2026Article
- Knowledge of Pre-Eclampsia and Its Risk Factors Among Pregnant Women Attending Antenatal Care in Lango Sub-Region, Northern Uganda.International journal of women's health · 2026Article
- Risk factors associated with progression from pre-eclampsia to eclampsia: A prospective cohort study and population-wide data analysis.Acta obstetricia et gynecologica Scandinavica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionEclampsia is a life-threatening complication of pre-eclampsia. There are currently no means of reliably identifying women with pre-eclampsia who are at the highest risk of progression to eclampsia and would thus benefit from prioritization for intensive monitoring and urgent delivery. This is particularly challenging in obstetric settings where resources are limited. We identify risk factors for the progression of pre-eclampsia to eclampsia in low- and middle-income settings. MATERIAL AND
methodsWomen diagnosed with pre-eclampsia were prospectively recruited at a single tertiary referral centre in urban Uganda (2011-2016). Multivariable logistic regression models were used to identify risk factors that predicted the likelihood of progression to eclampsia. Key findings were validated in a geographically, socioeconomically, and ethnically distinct population using population-wide hospital admission data from Ecuador (2021-2023).
resultsIn urban Uganda, progression from pre-eclampsia to eclampsia was associated with nulliparity (OR 2.4; 95% CI: 1.1-5.4, p = 0.03), Baganda ethnicity (OR 1.9; 95% CI: 1.1-3.9, p = 0.01), unskilled/unemployed paternal occupation (OR 2.8; 95% CI: 1.3-6.4, p = 0.03), and a trend toward younger maternal age (OR 0.9; 95% CI: 0.9-1.0 per year; p = 0.09). Risk of progression to eclampsia was not related to the severity of pre-eclampsia or the number of antenatal clinic visits. In Ecuador, population-wide analysis showed that progression to eclampsia was associated with younger maternal age (p < 0.001) and a trend toward public vs privately funded obstetric care (p = 0.09).
conclusionsEclampsia risk extends beyond clinical markers of pre-eclampsia severity, with socioeconomic factors and maternal age playing crucial roles in disease progression. A targeted, context-specific approach prioritizing high-risk young women with socioeconomic vulnerabilities could optimize healthcare resources and mitigate severe hypertensive disorder risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.